References in periodicals archive ?
Hatchtech's DeOvo(TM), a topical formulation of a known metalloprotease inhibitor, has shown both ovicidal and lousicidal activity and offers the potential for a more effective treatment following a single application.
Hatchtech's proprietary agent DeOvo(TM) is a topical formulation of a known metalloprotease inhibitor which targets certain proteases that are key to biological processes involved in insect hatch and survival.
Nasdaq: AGPH) today announced initiation of phase II/III clinical trials, in patients with advanced lung or prostate cancer, to evaluate an experimental anticancer agent known as AG3340, a matrix metalloprotease inhibitor with potent anti-angiogenesis activity.